Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PORCN | Q9H237 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16440384 | 0.85 | MAPT (0.73) | MAPTSMN1; SMN2LMNARXFP1CYP1A2 | |
| SCHEMBL10114670 | 0.85 | MAPT (0.82) | MAPTSMN1; SMN2LMNARXFP1CYP1A2 | |
| SCHEMBL18166618 | 0.85 | MAPT (0.79) | MAPTSMN1; SMN2LMNARXFP1CYP1A2 | |
| SCHEMBL9972920 | 0.84 | MAPT (0.77) | MAPTSMN1; SMN2LMNARXFP1CYP1A2 | |
| SCHEMBL18166649 | 0.84 | SMN1; SMN2 (0.82) | MAPTSMN1; SMN2LMNARXFP1CYP1A2 | |
| SCHEMBL18166643 | 0.84 | RXFP1 (0.72) | MAPTSMN1; SMN2LMNARXFP1CYP1A2 | |
| SCHEMBL27793543 | 0.84 | MAPT (0.79) | MAPTSMN1; SMN2LMNARXFP1CYP1A2 | |
| SCHEMBL18166709 | 0.83 | SMN1; SMN2 (0.73) | MAPTSMN1; SMN2LMNARXFP1CYP1A2 | |
| SCHEMBL10114087 | 0.83 | MAPT (1.00) | MAPTSMN1; SMN2LMNARXFP1CYP1A2 | |
| SCHEMBL3266103 | 0.83 | MAPT (0.79) | MAPTSMN1; SMN2LMNARXFP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3663295-A1 | 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL | ELI LILLY AND CO. (US) | 2020-06-10 | — | — | EP | disclosed |
| EP-3184527-A1 | 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL | Hydra Biosciences, Inc. (US) | 2017-06-28 | — | — | EP | disclosed |
| US-20170066759-A1 | AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY | SHIONOGI & CO (JP) | 2017-03-09 | — | — | US | disclosed |
| US-9499533-B2 | Aromatic 5-membered heterocyclic derivative having TRPV4-Inhibiting activity | SHIONOGI & CO., LTD. (JP) | 2016-11-22 | — | — | US | disclosed |
| EP-2170309-B1 | 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL | HYDRA BIOSCIENCES INC (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20150038483-A1 | AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2015-02-05 | — | — | US | disclosed |
| EP-2832731-A1 | AROMATIC HETEROCYCLIC FIVE-MEMBERED RING DERIVATIVE HAVING TRPV4 INHIBITORY ACTIVITY | Shionogi & Co., Ltd. (JP) | 2015-02-04 | — | — | EP | disclosed |
| CN-101801362-B | Methods and compositions for treating disorders | HYDRA BIOSCIENCES INC | 2014-01-22 | — | — | CN | disclosed |
| CN-101801362-A | methods and compositions for treating disorders | HYDRA BIOSCIENCES INC | 2010-08-11 | — | — | CN | disclosed |
| WO-2010036821-A1 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS | HYDRA BIOSCIENCES, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066759-A1 | AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY | TRPV4, TRPC4, TRPV2 | MAPT 4306/4885SMN1; SMN2 3980/4885LMNA 2584/4885 |
| US-20150038483-A1 | AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY | TRPV4, TRPC4, TRPV2 | MAPT 4306/4885SMN1; SMN2 3980/4885LMNA 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.